These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19635186)

  • 1. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.
    Bruserud Ø; Håvardstein K
    Hematology; 2009 Aug; 14(4):224-6. PubMed ID: 19635186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura.
    Provan D; Moss AJ; Newland AC; Bussel JB
    Am J Hematol; 2006 Jan; 81(1):19-25. PubMed ID: 16369979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.
    Sharma AP; Filler G
    Pediatr Nephrol; 2009 Feb; 24(2):423-4. PubMed ID: 18853197
    [No Abstract]   [Full Text] [Related]  

  • 4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil.
    Vasoo S; Thumboo J; Fong KY
    Lupus; 2003; 12(8):630-2. PubMed ID: 12945723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura.
    Hou M; Peng J; Shi Y; Zhang C; Qin P; Zhao C; Ji X; Wang X; Zhang M
    Eur J Haematol; 2003 Jun; 70(6):353-7. PubMed ID: 12756016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura.
    Zhang WG; Ji L; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Zou SP
    Acta Pharmacol Sin; 2005 May; 26(5):598-602. PubMed ID: 15842780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR; Segel E; Brandsborg M; d'Amore F
    Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.
    Kotb R; Pinganaud C; Trichet C; Lambotte O; Dreyfus M; Delfraissy JF; Tchernia G; Goujard C
    Eur J Haematol; 2005 Jul; 75(1):60-4. PubMed ID: 15946312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
    An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
    Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
    Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.
    Pranzatelli MR; Tate ED; Travelstead AL; Baumgardner CA; Gowda NV; Halthore SN; Kerstan P; Kossak BD; Mitchell WG; Taub JW
    J Child Neurol; 2009 Mar; 24(3):316-22. PubMed ID: 19258290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
    Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
    Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.